Scarica l'app Stockscreener
58.34
1.88%
-1.12
Dopo l'orario di chiusura:
55.50
-2.84
-4.87%
Precedente Chiudi:
$59.46
Aprire:
$59.6
Volume 24 ore:
2.44M
Relative Volume:
0.85
Capitalizzazione di mercato:
$11.04B
Reddito:
$2.83B
Utile/perdita netta:
$-1.02B
Rapporto P/E:
-10.59
EPS:
-5.51
Flusso di cassa netto:
$194.14M
1 W Prestazione:
+2.86%
1M Prestazione:
+6.52%
6M Prestazione:
+33.38%
1 anno Prestazione:
-15.86%
Intervallo 1D:
$57.91
$59.66
Intervallo di 1 settimana:
$56.38
$60.26
Portata 52W:
$38.81
$72.83
Exact Sciences Corp Stock (EXAS) Company Profile
Nome
Exact Sciences Corp
Settore
Industria
Telefono
608-284-5700
Indirizzo
5505 ENDEAVOR LANE, MADISON, WI
Confronta EXAS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
58.34 | 11.26B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
524.80 | 201.90B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
202.46 | 146.42B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
616.15 | 50.30B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
136.62 | 39.72B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
198.17 | 34.51B | 15.70B | 1.24B | 2.01B | 6.9036 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-27 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-01-02 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-08-02 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2023-05-05 | Iniziato | UBS | Neutral |
| 2023-03-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-02-10 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Downgrade | Craig Hallum | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Neutral |
| 2021-11-03 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Reiterato | BTIG Research | Buy |
| 2021-07-29 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-29 | Reiterato | Oppenheimer | Outperform |
| 2021-07-29 | Reiterato | Stifel | Buy |
| 2021-06-15 | Iniziato | Raymond James | Strong Buy |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Equal Weight |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-10-29 | Downgrade | UBS | Buy → Neutral |
| 2020-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-08 | Ripresa | BTIG Research | Buy |
| 2020-04-02 | Iniziato | Evercore ISI | Outperform |
| 2020-01-10 | Ripresa | BTIG Research | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Dougherty & Company | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-17 | Reiterato | BofA/Merrill | Buy |
| 2019-10-01 | Ripresa | Craig Hallum | Buy |
| 2019-09-26 | Iniziato | Oppenheimer | Outperform |
| 2019-02-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-09 | Iniziato | UBS | Buy |
| 2018-09-05 | Ripresa | The Benchmark Company | Hold |
| 2018-08-13 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-01-29 | Iniziato | Goldman | Neutral |
| 2018-01-08 | Reiterato | The Benchmark Company | Buy |
| 2017-11-13 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Downgrade | BTIG Research | Buy → Neutral |
Mostra tutto
Exact Sciences Corp Borsa (EXAS) Ultime notizie
Published on: 2025-10-12 23:07:32 - newser.com
EXACT Sciences Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
What’s the recovery path for long term holders of Exact Sciences CorporationNew Guidance & Safe Entry Trade Reports - newser.com
Exact Sciences Corporation $EXAS Shares Sold by Blair William & Co. IL - MarketBeat
Doyle, Exact Sciences director, sells $120k in shares By Investing.com - Investing.com Australia
Herriott James, Exact Sciences SVP, sells $90k in EXAS stock - Investing.com Canada
Insider Sell: James Doyle Sells 2,000 Shares of Exact Sciences C - GuruFocus
Can Exact Sciences Corporation (EXK) stock sustain institutional flowsJuly 2025 Final Week & Daily Profit Focused Stock Screening - newser.com
Here's Why Exact Sciences (EXAS) is a Strong Momentum Stock - Yahoo Finance
What analysts say about Exact Sciences Corporation EXK stockFibonacci Extensions & Free Unmatched Market Gains - earlytimes.in
Exact Sciences (EXAS): Taking Stock of Valuation Following Recent Share Price Momentum - Yahoo Finance
Piper Sandler raises Exact Sciences stock price target to $70 on Cologuard growth - Investing.com India
EXAS: Piper Sandler Raises Price Target to $70, Maintains Overwe - GuruFocus
Piper Sandler raises Exact Sciences stock price target to $70 on Cologuard growth By Investing.com - Investing.com South Africa
Exact Sciences (NASDAQ:EXAS) Upgraded at Zacks Research - MarketBeat
Exact Sciences Corporation $EXAS Shares Bought by Gagnon Securities LLC - MarketBeat
Press Release: Exact Sciences Schedules Third Quarter 2025 Earnings Call - 富途牛牛
Exact Sciences Schedules Third Quarter 2025 Earnings Call - Business Wire
Exact Sciences Corporation $EXAS Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Evercore ISI Group Raises Price Target for EXAS to $68.00 | EXAS Stock News - GuruFocus
Are Medical Stocks Lagging Exact Sciences (EXAS) This Year? - Yahoo Finance
Here's How Much a $1000 Investment in Exact Sciences Made 10 Years Ago Would Be Worth Today - Yahoo Finance
Study finds Cologuard Plus efficient for colorectal cancer screening By Investing.com - Investing.com Nigeria
Study finds Cologuard Plus efficient for colorectal cancer screening - Investing.com
New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest Colonoscopies - Yahoo Finance
Real time pattern detection on Exact Sciences Corporation stockWeekly Profit Analysis & Weekly High Momentum Picks - newser.com
Why Exact Sciences Corporation stock is in analyst buy zone2025 Investor Takeaways & Weekly Momentum Picks - newser.com
Will Exact Sciences Corporation see short term momentumTrade Ideas & Fast Moving Market Watchlists - newser.com
How Recent Developments Are Reshaping the Story for Exact Sciences - Yahoo Finance
Will Analyst Upgrades and Earnings Revisions Shift Exact Sciences' (EXAS) Investment Narrative? - simplywall.st
Exact Sciences (EXAS): Evaluating Upside Potential as Analyst Optimism and New Catalysts Drive Attention - simplywall.st
Best data tools to analyze Exact Sciences Corporation stockTrade Risk Summary & Technical Pattern Based Signals - newser.com
Will Exact Sciences Corporation (EXK) stock announce special dividendEarnings Beat & Accurate Entry and Exit Point Alerts - newser.com
How sentiment analysis helps forecast Exact Sciences Corporation2025 Valuation Update & Safe Capital Growth Stock Tips - newser.com
Using economic indicators to assess Exact Sciences Corporation potentialTrade Risk Assessment & Precise Trade Entry Recommendations - newser.com
Will Exact Sciences Corporation stock deliver consistent dividendsWeekly Gains Report & Capital Efficiency Focused Strategies - newser.com
Is Exact Sciences Corporation forming a reversal patternJuly 2025 Snapshot & Stock Portfolio Risk Control - newser.com
EXAS: Barclays Raises Price Target to $65.00 Amid Overweight Rat - GuruFocus
Here's Why Exact Sciences (EXAS) is a Strong Growth Stock - Yahoo Finance
Exact Sciences (EXAS) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Published on: 2025-10-01 06:45:18 - newser.com
Benchmark raises Exact Sciences stock price target to $60 on cancer test launch - Investing.com
Archford Capital Strategies LLC Acquires New Holdings in Exact Sciences Corporation $EXAS - MarketBeat
Using portfolio simulators with Exact Sciences Corporation included2025 Stock Rankings & Consistent Profit Alerts - newser.com
Exact Sciences Corporation $EXAS Shares Sold by Park Avenue Securities LLC - MarketBeat
Exact Sciences Corp Azioni (EXAS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Exact Sciences Corp Azioni (EXAS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Doyle James Edward | Director |
Oct 09 '25 |
Sale |
60.00 |
2,000 |
120,000 |
57,962 |
0.17%
2.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):